SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Biocept from the initial public offering are expected to be $19,000,000, before underwriting discounts and commissions and other offering expenses. Biocept has granted the representative of the underwriters a 45-day option to purchase up to 285,000 additional shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Capital Market under the symbol "BIOC" on February 5, 2014 and the offering is expected to close on February 10, 2014, subject to customary closing conditions.
Aegis Capital Corp. and Feltl and Company, Inc. are acting as joint book-running managers for the offering.
MLV & Co. LLC is acting as a co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 4, 2014.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: firstname.lastname@example.org. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its technology platforms to help improve individual patient treatment. Biocept has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce tests for other solid tumors.
CONTACT: Investor Contact: The Ruth Group Lee Roth/David Burke (646) 536-7012 / 646-536-7009 email@example.com / firstname.lastname@example.org Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023 email@example.comSource:Biocept, Inc.